%0 Journal Article
%A Desai, Ami V
%A Bagchi, Aditi
%A Armstrong, Amy E
%A van Tilburg, Cornelis M
%A Basu, Ellen M
%A Robinson, Giles W
%A Wang, Huanmin
%A Casanova, Michela
%A André, Nicolas
%A Campbell-Hewson, Quentin
%A Wu, Yeming
%A Cardenas, Alison
%A Ci, Bo
%A Ryklansky, Carolina
%A Devlin, Clare E
%A Meneses-Lorente, Georgina
%A Wulff, Jade
%A Hutchinson, Katherine E
%A Gajjar, Amar
%A Fox, Elizabeth
%T Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions.
%J European journal of cancer
%V 220
%@ 0959-8049
%C Amsterdam [u.a.]
%I Elsevier
%M DKFZ-2025-00560
%P 115308
%D 2025
%X Entrectinib, a central nervous system (CNS)-penetrant TRK/ROS1 inhibitor, has demonstrated clinical activity in children with NTRK1/2/3 or ROS1 fusion-positive extracranial solid and CNS tumours. We present integrated data of entrectinib in children with NTRK or ROS1 fusion-positive tumours from the STARTRK-NG, TAPISTRY, and STARTRK-2 trials.Efficacy analyses were undertaken on TRK/ROS1 inhibitor-naïve patients aged <18 years with metastatic/locally advanced NTRK1/2/3 or ROS1 fusion-positive extracranial solid or CNS tumours who received ≥1 entrectinib dose and had ≥6 months of follow-up from enrolment. Tumour responses were confirmed by blinded independent central review (BICR) per RECIST v1.1/RANO criteria.BICR-assessed confirmed objective response rate (cORR). Key secondary endpoints: duration of response (DoR); time to response (TtR); safety.As of 16 July 2023, out of 91 safety-evaluable patients, 64 (NTRK: n=44; ROS1: n=20) were efficacy evaluable. In the NTRK and ROS1 subgroups, respectively, median age was 4.0 years and 7.5 years; median survival follow-up was 24.2 months and 27.6 months. cORR was 72.7 
%K CNS tumours (Other)
%K Entrectinib (Other)
%K NTRK fusions (Other)
%K Paediatric tumours (Other)
%K ROS1 fusions (Other)
%K ROS1 inhibitor (Other)
%K STARTRK-2 (Other)
%K STARTRK-NG (Other)
%K TAPISTRY (Other)
%K TRK inhibitor (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40086048
%R 10.1016/j.ejca.2025.115308
%U https://inrepo02.dkfz.de/record/299823